# PLATFORM Study of Precision Medicine for Rare Tumors

> **NCT04423185** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 770 (estimated)

## Conditions studied

- Rare Tumor

## Interventions

- **DRUG:** Almonertinib 110 MG
- **DRUG:** Dacomitinib 45 MG
- **DRUG:** Alectinib 150 MG
- **DRUG:** Crizotinib 250 MG
- **DRUG:** Pyrotinib 160/80 MG
- **DRUG:** Imatinib 400 MG
- **DRUG:** Niraparib 200/300 MG
- **DRUG:** Palbociclib 125mg
- **DRUG:** Vemurafenib 240 MG
- **DRUG:** Sintilimab 100MG
- **DRUG:** Atezolizumab 1680 MG

## Key facts

- **NCT ID:** NCT04423185
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-15
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 770 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04423185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04423185, "PLATFORM Study of Precision Medicine for Rare Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04423185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*